首页> 美国卫生研究院文献>Cancer Science >Determination of c‐erbB‐2 Protein in Primary Breast Cancer Tissue Extract Using an Enzyme Immunoassay
【2h】

Determination of c‐erbB‐2 Protein in Primary Breast Cancer Tissue Extract Using an Enzyme Immunoassay

机译:酶联免疫法测定原发性乳腺癌组织提取物中的c-erbB-2蛋白

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The c‐erbB‐2 protein in breast cancer tissue extract was determined by using an enzyme‐immunoassay (EIA) to see whether the quantitative determination of the oncoprotein correlates with the results of immunohistochemistry and other prognostic factors. Primary breast cancer from 104 patients was assayed for c‐erbB‐2 protein with an EIA that used two monoclonal antibodies directed against the extracellular domain of the protein. Pelleted tissue homogenate prepared routinely for hormone receptor assay was used as the starting material. The mean quantity of c‐erbB‐2 protein was 695 unit/mg protein (range 23 to 5939), and this correlated well with the results of immunohistochemical staining (P< 0.00001). It was found that 17.3%(18/104) of all tumors contained amounts of c‐erbB‐2 protein exceeding 1000 units/mg protein. All tumors with negative or weakly positive staining contained the oncoprotein as less than 1000 units/ing protein. The content of c‐erbB‐2 protein was correlated with the histologic grade (P=0.0022), mitotic index (P=0.0002) and degree of nuclear atypia (P=0.013). It was inversely correlated with progesterone receptor (P=0.006) and less strongly with estrogen receptor status (P=0.016). Values of hormone receptor concentration and c‐erbB‐2 protein content showed a hyperbolic relationship that suggested biological interactions between c‐erbB‐2 protein and steroid hormone receptors. We conclude that c‐erbB‐2 protein in tissue extracts of primary breast cancer can be determined reliably by EIA, and it seems feasible to explore further the advantages of introducing EIA as a routine laboratory examination for providing additional information about the biological aspects of breast cancer.
机译:乳腺癌组织提取物中的c-erbB-2蛋白通过酶免疫测定(EIA)进行测定,以查看癌蛋白的定量测定是否与免疫组织化学结果和其他预后因素相关。使用EIA分析了104位患者的原发性乳腺癌中c-erbB-2蛋白,该蛋白使用了两种针对该蛋白胞外域的单克隆抗体。常规制备用于激素受体测定的球状组织匀浆用作起始材料。 c-erbB-2蛋白的平均数量为695单位/ mg蛋白(范围23至5939),这与免疫组织化学染色的结果密切相关(P <0.00001)。发现所有肿瘤中有17.3%(18/104)的c-erbB-2蛋白含量超过1000单位/ mg蛋白。所有染色为阴性或弱阳性的肿瘤均含有少于1000单位蛋白的癌蛋白。 c-erbB-2蛋白的含量与组织学分级(P = 0.0022),有丝分裂指数(P = 0.0002)和核非典型性程度(P = 0.013)相关。它与孕激素受体呈负相关(P = 0.006),与雌激素受体状态呈负相关(P = 0.016)。激素受体浓度和c-erbB-2蛋白含量的值呈双曲线关系,表明c-erbB-2蛋白与类固醇激素受体之间存在生物学相互作用。我们得出的结论是,通过EIA可以可靠地确定原发性乳腺癌组织提取物中的c-erbB-2蛋白,并且进一步探索引入EIA作为常规实验室检查以提供有关乳腺癌生物学方面信息的优势似乎是可行的癌症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号